Previous Close | 0.0080 |
Open | 0.0067 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.0067 - 0.0080 |
52 Week Range | 0.0055 - 0.1000 |
Volume | |
Avg. Volume | 562,769 |
Market Cap | 805,024 |
Beta (5Y Monthly) | 2.59 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
MIAMI, April 19, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its MetaHealthU mobile application platform will focus on determining the cause and finding a possible cure for hallucinogen-persisting perception disorder (HPPD). Ehave has pioneered HPPD research efforts by launching a series of studies through its partnership with the University of Melbourne to gather data and bio-markers to target the
Mycotopia Therapies and Ei.Ventures are moving forward with plans to form PSLY.COM; HAVN Life Sciences' functional mushrooms will be used in PSLY.COM’s MANA products, its line of whole-plant based medicinal mushroom nutraceuticals being developed for the consumer marketMIAMI, March 21, 2022 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics, announced today plans to enter
Agreement with Heally adds doctors, licensed psychotherapists and registered nurses to the KetaDASH platformWith the opening of KetaDASH, Ehave builds momentum for the psychedelic renaissance in the mental health fieldBoth the KetaDASH patient and nurse connect to a psychotherapist via Heally’s telehealth portal for each treatment session MIAMI, March 03, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today